<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02947152</url>
  </required_header>
  <id_info>
    <org_study_id>CHKT288X2101</org_study_id>
    <nct_id>NCT02947152</nct_id>
  </id_info>
  <brief_title>HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma</brief_title>
  <official_title>A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of HKT288, Administered Intravenously in Adult Patients With Advanced Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A first-in-human study using HKT288 in solid tumors, including epithelial ovarian cancer and&#xD;
      renal cell carcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Actual">September 14, 2017</completion_date>
  <primary_completion_date type="Actual">September 14, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs) in the DLT evaluation period</measure>
    <time_frame>evaluation period is 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by overall incidence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Until 105 days after last dose of study treatment (=average of approximately 6 months after first dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability as assessed by numbers of dose changes or interruptions</measure>
    <time_frame>Until last dose of study treatment (=average of approximately 6 months after first dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety assessed by severity of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Until 105 days after last dose of study treatment (=average of approximately 6 months after first dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration vs. time profiles of total antibody (tAb)</measure>
    <time_frame>On treatment up to Cycle 6 Day 1 and at the time of study treatment discontinuation (=average of approximately 6 months after first dose). 1 cycle is 21 days, increases to 28 days if there is a dose delay of 7 days for the start of next dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>every 2 cycles up to Cycle 17 and every 3 cycles thereafter until study treatment discontinuation (=average of approximately 6 months after first dose). Then every 9 weeks until end of disease progression follow-up (up to 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>every 2 cycles up to Cycle 17 and every 3 cycles thereafter until study treatment discontinuation (=average of approximately 6 months after first dose). Then every 9 weeks until end of disease progression follow-up (up to 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>every 2 cycles up to Cycle 17 and every 3 cycles thereafter until study treatment discontinuation (=average of approximately 6 months after first dose). Then every 9 weeks until end of disease progression follow-up (up to 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>At 6 months on treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
    <time_frame>every 2 cycles up to Cycle 17 and every 3 cycles thereafter until study treatment discontinuation (=average of approximately 6 months after first dose). Then every 9 weeks until end of disease progression follow-up (up to 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-HKT288 antibodies.</measure>
    <time_frame>On treatment up to Cycle 6 Day 1 and at the time of study treatment discontinuation (=average of approximately 6 months after first dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDH6 expression level</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) parameter (AUC) for HKT288</measure>
    <time_frame>On treatment up to Cycle 6 Day 1 and at the time of study treatment discontinuation (=average of approximately 6 months after first dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) for HKT288</measure>
    <time_frame>On treatment up to Cycle 6 Day 1 and at the time of study treatment discontinuation (=average of approximately 6 months after first dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) for HKT288</measure>
    <time_frame>On treatment up to Cycle 6 Day 1 and at the time of study treatment discontinuation (=average of approximately 6 months after first dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters (half-life) for HKT288</measure>
    <time_frame>On treatment up to Cycle 6 Day 1 and at the time of study treatment discontinuation (=average of approximately 6 months after first dose)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Dose escalation part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer) and clear cell or papillary renal cell carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion part (RCC arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Includes patients with clear cell or papillary renal cell carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion part (ovarian cancer arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HKT288</intervention_name>
    <description>Cadherin-6-targeting antibody-drug conjugate for intravenous administration</description>
    <arm_group_label>Dose escalation part</arm_group_label>
    <arm_group_label>Dose expansion part (RCC arm)</arm_group_label>
    <arm_group_label>Dose expansion part (ovarian cancer arm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Advanced (metastatic or locally advanced) serous epithelial ovarian, serous fallopian&#xD;
             tubal or serous primary peritoneal cancer or advanced clear cell or papillary renal&#xD;
             cell carcinoma who have received or are intolerant to all therapy known to confer&#xD;
             clinical benefit for their disease, as determined by the investigator.&#xD;
&#xD;
          -  Tumor sample is available for retrospective CDH6 expression testing&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance status ≤2&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Patient has central nervous system metastatic involvement. Patients with previously&#xD;
             treated CNS metastases are also excluded.&#xD;
&#xD;
          -  Patient with any active or chronic corneal disorders&#xD;
&#xD;
          -  Patients with monocular vision or have media opacities or any other condition that&#xD;
             precludes monitoring of the retina or fundus.&#xD;
&#xD;
          -  Patients with a history of serious allergic reactions&#xD;
&#xD;
          -  Patients with QTcF &gt;470 msec at screening ECG or congenital long QT syndrome&#xD;
&#xD;
          -  Any prior history of treatment with maytansine (DM1 or DM4)-based ADC&#xD;
&#xD;
          -  Patient have received anti-cancer therapies within the following time frames prior to&#xD;
             the first dose of study treatment:&#xD;
&#xD;
               -  Conventional cytotoxic chemotherapy: ≤4 weeks (≤ 6 weeks for nitrosoureas and&#xD;
                  mitomycin-C)&#xD;
&#xD;
               -  Biologic therapy (e.g., antibodies): ≤4 weeks&#xD;
&#xD;
               -  Non-cytotoxic small molecule therapeutics: ≤5 half-lives or ≤2 weeks (whichever&#xD;
                  is longer)&#xD;
&#xD;
               -  Other investigational agents: ≤4 weeks&#xD;
&#xD;
               -  Radiation therapy (except for localized radiotherapy for analgesic purpose or for&#xD;
                  lytic lesions at risk of fracture): ≤4 weeks&#xD;
&#xD;
               -  Radiation therapy (localized radiotherapy for analgesic purpose or for lytic&#xD;
                  lesions at risk of fracture) ≤2 weeks&#xD;
&#xD;
               -  Major surgery: ≤2 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466 8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Locarno</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17224</url>
    <description>Results for CHKT288X2101 can be found on the Novartis Clinical Trials Results Website</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2016</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HKT288</keyword>
  <keyword>CDH6</keyword>
  <keyword>ADC</keyword>
  <keyword>maytansine</keyword>
  <keyword>epithelial ovarian cancer</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>RCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

